A Phase II, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution Compared With Placebo in Subjects With Mild or Moderate Myopia (APPLE)
Latest Information Update: 27 Aug 2020
Price :
$35 *
At a glance
- Drugs Atropine (Primary)
- Indications Myopia
- Focus Therapeutic Use
- Acronyms APPLE
- Sponsors Santen Pharmaceutical
- 25 Aug 2020 Status changed from active, no longer recruiting to completed.
- 23 Dec 2019 Results published in the Santen Pharmaceutical Media Release.
- 23 Dec 2019 Primary endpoint has been met. (Spherical equivalent), according to an Santen Pharmaceutical media release.